Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises
08:16am, Friday, 26'th Jul 2024
Eli Lilly (LLY) shares dropped more than 4% on Thursday, continuing a hasty retreat from their record high earlier this month, as investors assessed the possible impact of a promising new weight-loss
Prediction: This Is What Eli Lilly Stock Will Do Next
07:45am, Friday, 26'th Jul 2024
Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space. With the stock closing in on $900 per share, I think there is a case to be made for a stock
Is Eli Lilly Stock Headed Toward $1300 Levels?
07:00am, Friday, 26'th Jul 2024
Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
07:06pm, Thursday, 25'th Jul 2024
A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.
7 Explosive Growth Stocks Set to Soar in 2024
05:17pm, Thursday, 25'th Jul 2024
Wall Street has rewarded certain growth stocks handsomely this year. I believe now may be an opportune time to buy some of these high-flyers, even after the recent tech selloff.
3 Top-Performing Stocks Beating the Big Names in 2024
02:29pm, Thursday, 25'th Jul 2024
After Wednesday's painful market-wide sell-off, investors seem more willing than ever to give up on the big-tech trade. Indeed, the Magnificent Seven was crushed as two members reported quarterly resu
3 Companies Gearing Up for a Stock Split
11:58am, Thursday, 25'th Jul 2024
Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
10:00am, Thursday, 25'th Jul 2024
INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that d
Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
08:40am, Thursday, 25'th Jul 2024
Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs. Approval of tirzepatide for weight management in China and the EU opens up new markets for the company. Despite strong
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
06:39am, Wednesday, 24'th Jul 2024
Eli Lilly has some exciting opportunities in weight loss in the future, but investors shouldn't overlook its impressive dividend. Broadcom's business is booming due to artificial intelligence, and tha
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
04:15am, Wednesday, 24'th Jul 2024
Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
06:52pm, Monday, 22'nd Jul 2024
In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.
Don't Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
03:52pm, Monday, 22'nd Jul 2024
We're still early in the second-quarter earnings cycle. So far, it has mostly been the banks and credit card companies that have reported Q2 results.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
03:11pm, Monday, 22'nd Jul 2024
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidat
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
02:53pm, Monday, 22'nd Jul 2024
HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.
